Pneumonia drug candidate wins fast-track designation from FDA

04/29/2013 | Pharmaceutical Business Review Online

The FDA granted fast-track status to Sanofi Pasteur and KaloBios Pharmaceuticals' KB001A, an experimental treatment for Pseudomonas aeruginosa-related pneumonia among people being treated with mechanical ventilation. The drug, a monoclonal antibody, is undergoing an early-stage study in the U.S.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ